Hyperkalemic Periodic Paralysis (HYPP)
Gene or Region: SCN4A
Reference Variant: C
Mutant Variant: G
Affected Breeds: Stock Horses
Research Confidence: High - Findings reproduced in multiple studies
Explanation of Results: HYPP/HYPP = homozygous for Hyperkalemic Periodic Paralysis, extreme trait expressed HYPP/n = heterozygous for Hyperkalemic Periodic Paralysis, trait expressed n/n = no variant detected
General Description for Hyperkalemic Periodic Paralysis (HYPP)
Hyperkalemic Periodic Paralysis (HYPP) is a dominant genetic disorder resulting from defects in sodium channels in the muscle. Affected animals experience episodes of muscular weakness or tremors, and can lead to paralysis, collapse, and sudden death. Heterozygous horses (HYPP/n) experience more moderate symptoms that can usually be managed through diet and exercise. However, homozygous horses (HYPP/HYPP) are much more severely affected, and some breed registries will not accept these animals.
Gene Information
SCN4A is a sodium channel involved in normal muscular control. Mutations in humans are well documented to cause HYPP. This mutation is a single base substitution that alters an amino acid, likely changing the function of the encoded protein. This was the first successfully mapped genetic disorder of the horse.
References
Rudolph JA et al., “Periodic paralysis in quarter horses: a sodium channel mutation disseminated by selective breeding.” (1992) Nat Genet. 2: 144-7. PMID:1338908
Bowling AT et al., “Evidence for a single pedigree source of the hyperkalemic periodic paralysis susceptibility gene in quarter horses.” (1996) Anim Genet. 27: 279-81. PMID: 8856926
Naylor JM et al., “Hyperkalaemic periodic paralysis in homozygous and heterozygous horses: a co-dominant genetic condition.” (1999) Equine Vet J. 31: 153-9. PMID: 10213428
Tryon RC et al., “Evaluation of allele frequencies of inherited disease genes in subgroups of American Quarter Horses.” (2009) J Am Vet Med Assoc. 234: 120-5. PMID: 19119976
More Horse Health
Equine Metabolic Syndrome / Laminitis Risk
Equine Metabolic Syndrome (EMS) is a wide-spread issue in the horse population. Primarily characterized by hyperinsulinemia (excess insulin circulating in the blood in relation to glucose levels), this metabolic disorder is often present in obese horses and ponies and can be challenging to diagnose as it can be misdiagnosed as "Cushing's" (a pituitary disfunction).
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.